- Home
- CABA vs BVFL Comparison
CABA vs BVFL Comparison
Compare CABA & BVFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- BVFL
- Stock Information
- Founded
- CABA 2017
- BVFL 1873
- Country
- CABA United States
- BVFL United States
- Employees
- CABA 167
- BVFL N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- BVFL Savings Institutions
- Sector
- CABA Health Care
- BVFL Finance
- Exchange
- CABA Nasdaq
- BVFL Nasdaq
- Market Cap
- CABA 174.7M
- BVFL 150.2M
- IPO Year
- CABA 2019
- BVFL N/A
- Fundamental
- Price
- CABA $2.04
- BVFL $16.61
- Analyst Decision
- CABA Strong Buy
- BVFL
- Analyst Count
- CABA 8
- BVFL 0
- Target Price
- CABA $12.75
- BVFL N/A
- AVG Volume (30 Days)
- CABA 1.3M
- BVFL 40.2K
- Earning Date
- CABA 11-13-2025
- BVFL 10-20-2025
- Dividend Yield
- CABA N/A
- BVFL N/A
- EPS Growth
- CABA N/A
- BVFL 27.09
- EPS
- CABA N/A
- BVFL 1.07
- Revenue
- CABA N/A
- BVFL $38,333,000.00
- Revenue This Year
- CABA N/A
- BVFL N/A
- Revenue Next Year
- CABA N/A
- BVFL N/A
- P/E Ratio
- CABA N/A
- BVFL $15.59
- Revenue Growth
- CABA N/A
- BVFL 2.48
- 52 Week Low
- CABA $0.99
- BVFL $13.53
- 52 Week High
- CABA $5.46
- BVFL $18.19
- Technical
- Relative Strength Index (RSI)
- CABA 71.47
- BVFL 56.39
- Support Level
- CABA $1.63
- BVFL $16.44
- Resistance Level
- CABA $1.74
- BVFL $16.74
- Average True Range (ATR)
- CABA 0.12
- BVFL 0.19
- MACD
- CABA 0.05
- BVFL -0.05
- Stochastic Oscillator
- CABA 89.44
- BVFL 46.94
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.